NextCure (FRA:2US0) Beginning Cash Position: €22.47 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2US0 NextCure Inc FRA:2US0
27 GF Score
Price €4.73
! 3 Warning Signs
View Full Analysis

What is NextCure Beginning Cash Position?

NextCure FRA:2US0 27 Beginning Cash Position is €22.47 Mil as of Mar. 2026. GuruFocus rates FRA:2US0 with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

NextCure's Beginning Cash Position for the quarter that ended in Mar. 2026 was €22.47 Mil.

NextCure's quarterly Beginning Cash Position increased from Sep. 2025 (€4.17 Mil) to Dec. 2025 (€23.59 Mil) but then declined from Dec. 2025 (€23.59 Mil) to Mar. 2026 (€22.47 Mil).

NextCure's annual Beginning Cash Position declined from Dec. 2023 (€24.42 Mil) to Dec. 2024 (€12.49 Mil) but then increased from Dec. 2024 (€12.49 Mil) to Dec. 2025 (€23.68 Mil).

NextCure Beginning Cash Position Related Terms

NextCure Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for NextCure's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCure Beginning Cash Position Chart

NextCure Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 32.11 11.65 24.42 12.49 23.68

NextCure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.65 18.92 4.17 23.59 22.47
FRA:2US0
27GF Score
NextCure Inc FRA:2US0
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCure Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €22.47 Mil mean?
NextCure (FRA:2US0) has a Beginning Cash Position of €22.47 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on NextCure and its competitors.
Is NextCure's Beginning Cash Position too high?
NextCure's current Beginning Cash Position is €22.47 Mil. Overall, NextCure has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does NextCure's Beginning Cash Position compare to LPCN and VYNE?
NextCure's Beginning Cash Position of €22.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on NextCure and its competitors. NextCure's current Beginning Cash Position is €22.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCure stock overvalued right now?
NextCure (FRA:2US0) has a current Beginning Cash Position of €22.47 Mil. The current Beginning Cash Position is €22.47 Mil. NextCure's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For NextCure (FRA:2US0), the current Beginning Cash Position is €22.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NextCure Business Description

Other Exchanges NXTC:USA
Address 9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
27GF Score

Get the complete analysis for FRA:2US0

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.73
Price